Jonathan Gootenberg

Dr. Jonathan Gootenberg earned his bachelor’s degree in mathematics and biological engineering at MIT. He received his PhD in Systems Biology from Harvard University, during which he conducted researches with Aviv Regev and Feng Zhang at the McGovern Institute and Broad Institute of MIT and Harvard. He is one of the first members of the McGovern Institute Fellows program, which aims to support the transition to independent research for exceptional recent PhD graduates. Dr. Jonathan Gootenberg explores biological diversity to develop tools for understanding and treating age-related disease. He draws from fundamental microbiology to engineer new molecular tools, which he applies to the study of aging. These tools, including the popular genome editing system CRISPR, allow for unprecedented manipulation and profiling of cellular states in the body, and have multiple applications in basic science, diagnostics, and therapeutics. Along with McGovern Fellow Omar Abudayyeh, Gootenberg uses gene editing, gene delivery, and cellular profiling methods to understand the changes that occur in the brain and other organs during aging, with the goal of generating new therapies for degenerative disease.

Lab Information

MIT McGovern Institute

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Aging 0 Molecular Tools 0 Gene Editing 0 Gene Delivery 0 Degenerative Disease 0 Diagnostics 0 Therapeutics 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (4)


This guy hasn’t posted anything yet.

Hot Posts for You

The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


  1. Joung, J., Ladha, A., Saito, M., Segel, M., Bruneau, R., Huang, M. L. W., ... & Greninger, A. L. (2020). Point-of-care testing for COVID-19 using SHERLOCK diagnostics. medRxiv.

  2. Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., ... & Lander, E. S. (2017). RNA targeting with CRISPR–Cas13. Nature, 550(7675), 280-284.

  3. Gootenberg, J. S., Abudayyeh, O. O., Lee, J. W., Essletzbichler, P., Dy, A. J., Joung, J., ... & Myhrvold, C. (2017). Nucleic acid detection with CRISPR-Cas13a/C2c2. Science, 356(6336), 438-442.

  4. Abudayyeh, O. O., Gootenberg, J. S., Konermann, S., Joung, J., Slaymaker, I. M., Cox, D. B., ... & Severinov, K. (2016). C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science, 353(6299).


This guy hasn’t plasmids anything yet.

Hot plasmids


This guy has no following anyone.

Popular Cloud Scientists

Cloud Scientists
  • Beate Escher photo

    Beate Escher

    Helmholtz Centre for Environmental Research–UFZ

  • Dimitri Kullmann photo

    Dimitri Kullmann

    UCL Queen Squaree Institute of Neurology

  • Changhao Bi photo

    Changhao Bi

    Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2020 MolecularCloud